-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
Both products are drugs for chronic diseases and are only sold by original manufacturers in China.
Idoxaban tosylate is a selective factor Xa inhibitor developed by Daiichi Sankyo, Japan.
It was first approved for venous thromboembolism in Japan in 2011, and several new indications have been approved since then.
At the end of 2018, idoxaban tosylate tablets were officially approved for import by the National Food and Drug Administration, bringing new options for anticoagulant therapy for domestic patients.
According to data from Mi Nei.
At present, only Hainan Simcere Pharmaceutical Co.
, Ltd.
Telmisartan amlodipine is a compound preparation composed of telmisartan (specific angiotensin II receptor antagonist) and amlodipine besylate (calcium antagonist), used to treat primary hypertension blood pressure.
At present, only Boehringer Ingelheim's Telmisartan and Amlodipine tablets are on sale in China, and Sichuan Pride Times Pharmaceutical has exclusively submitted the application for the marketing of this product as a generic drug.
Sichuan Pride Times Pharmaceutical submitted a listing application for telmisartan and amlodipine tablets in October 2018 with imitations of category 3, and entered the administrative approval stage in May 2021, and is expected to win the first imitation.
( Minenet database, official website of State Food and Drug Administration, etc.
Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
Both products are drugs for chronic diseases and are only sold by original manufacturers in China.
Idoxaban tosylate is a selective factor Xa inhibitor developed by Daiichi Sankyo, Japan.
It was first approved for venous thromboembolism in Japan in 2011, and several new indications have been approved since then.
At the end of 2018, idoxaban tosylate tablets were officially approved for import by the National Food and Drug Administration, bringing new options for anticoagulant therapy for domestic patients.
According to data from Mi Nei.
At present, only Hainan Simcere Pharmaceutical Co.
, Ltd.
Telmisartan amlodipine is a compound preparation composed of telmisartan (specific angiotensin II receptor antagonist) and amlodipine besylate (calcium antagonist), used to treat primary hypertension blood pressure.
At present, only Boehringer Ingelheim's Telmisartan and Amlodipine tablets are on sale in China, and Sichuan Pride Times Pharmaceutical has exclusively submitted the application for the marketing of this product as a generic drug.
Sichuan Pride Times Pharmaceutical submitted a listing application for telmisartan and amlodipine tablets in October 2018 with imitations of category 3, and entered the administrative approval stage in May 2021, and is expected to win the first imitation.
( Minenet database, official website of State Food and Drug Administration, etc.
)
